Downregulation of IL-17-producing T cells is associated with regulatory T cell expansion and disease progression in chronic lymphocytic leukemia
- 523 Downloads
Little is known about the immunobiology of interleukin-17 (IL-17)-producing T cells and regulatory T cells (Treg) in chronic lymphocytic leukemia (CLL). In this study, the frequencies of Th17, Tc17, and CD39+ Treg cells were enumerated in peripheral T cells isolated from 40 CLL patients and 15 normal subjects by flow cytometry. Our results showed a lower frequency of Th17 and Tc17 cells in progressive (0.99 ± 0.12 % of total CD3+CD4+ cells; 0.44 ± 0.09 % of total CD8+ cells) compared to indolent patients (1.57 ± 0.24 %, p = 0.042; 0.82 ± 0.2 %, p = 0.09) and normal subjects (1.78 ± 0.2 %, p = 0.003; 0.71 ± 0.09 %, p = 0.04). Decrease in IL-17-producing T cells was associated with CD39+ Treg cells expansion. Variation of IL-17-producing cells and Treg cells in indolent and progressive patients was neither associated to the expression levels of Th1- and Th2-specific transcription factors T-bet and GATA-3 nor to the frequencies of IFN-γ and IL-4-producing CD4+ T cells in a selected number of samples. Additionally, suppressive potential of CD4+ Treg was similar in CLL patients and normal subjects. Our data indicate that progression of CLL is associated with downregulation of IL-17-producing T cells and expansion of Treg cells, implying contribution of these subsets of T cells in the progression of CLL.
KeywordsTh17 Tc17 Regulatory T cell Chronic lymphocytic leukemia Interleukin 17
We would like to thank Mehdi Yousefi, Tahereh Shahrestani, and Bita Ansaripour for their excellent technical support. This study was supported in part by a grant from Tehran University of Medical Sciences (grant number 9879).
Conflicts of interest
- 2.Hojjat-Farsangi M, Jeddi-Tehrani M, Razavi SM, Sharifian RA, Mellstedt H, Shokri F, et al. Immunoglobulin heavy chain variable region gene usage and mutational status of the leukemic B cells in Iranian patients with chronic lymphocytic leukemia. Cancer Sci. 2009;100:2346–53.PubMedCrossRefGoogle Scholar
- 24.Jadidi-Niaragh F, Jeddi-Tehrani M, Ansaripour B, Razavi SM, Sharifian RA, Shokri F: Reduced frequency of NKT-like cells in patients with progressive chronic lymphocytic leukemia. Med Oncol. 2012;29(5):3561–9.Google Scholar
- 29.Jaffe ES. The 2008 who classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2009:523-531.Google Scholar
- 31.Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the national cancer institute–working group 1996 guidelines. Blood. 2008;111:5446–56.PubMedCrossRefGoogle Scholar
- 37.Jadidi-Niaragh F, Mirshafiey A: The deviated balance between regulatory T cell and th17 in autoimmunity. Immunopharmacol Immunotoxicol. 2012;34(5):727–39.Google Scholar
- 59.Pourgheysari B, Bruton R, Parry H, Billingham L, Fegan C, Murray J, et al. The number of cytomegalovirus-specific Cd4+ T cells is markedly expanded in patients with B-cell chronic lymphocytic leukemia and determines the total Cd4+ T-cell repertoire. Blood. 2010;116:2968–74.PubMedCrossRefGoogle Scholar
- 60.Walton JA, Lydyard PM, Nathwani A, Emery V, Akbar A, Glennie MJ, et al. Patients with B cell chronic lymphocytic leukaemia have an expanded population of Cd4 perforin expressing T cells enriched for human cytomegalovirus specificity and an effector-memory phenotype. Br J Haematol. 2010;148:274–84.PubMedCrossRefGoogle Scholar
- 61.Lindqvist CA, Christiansson LH, Thorn I, Mangsbo S, Paul-Wetterberg G, Sundstrom C, et al. Both Cd4+ Foxp3+ and Cd4+ Foxp3- T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro. Immunology. 2011;133:296–306.PubMedCrossRefGoogle Scholar